159 related articles for article (PubMed ID: 37706220)
1. Research progress on tamoxifen and its analogs associated with nuclear receptors.
Dong N; Du Y; Zheng Y; Zhang H; Lv H; Yan Z
Future Med Chem; 2023 Aug; 15(15):1427-1442. PubMed ID: 37706220
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of novel 4-hydroxytamoxifen analogs as estrogen-related receptor gamma inverse agonists.
Kim J; Chin J; Im CY; Yoo EK; Woo S; Hwang HJ; Cho JH; Seo KA; Song J; Hwang H; Kim KH; Kim ND; Yoon SK; Jeon JH; Yoon SY; Jeon YH; Choi HS; Lee IK; Kim SH; Cho SJ
Eur J Med Chem; 2016 Sep; 120():338-52. PubMed ID: 27236015
[TBL] [Abstract][Full Text] [Related]
3. ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.
Heckler MM; Thakor H; Schafer CC; Riggins RB
FEBS J; 2014 May; 281(10):2431-42. PubMed ID: 24684682
[TBL] [Abstract][Full Text] [Related]
4. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ.
Yu DD; Huss JM; Li H; Forman BM
Bioorg Med Chem; 2017 Mar; 25(5):1585-1599. PubMed ID: 28189393
[TBL] [Abstract][Full Text] [Related]
6. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
7. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
[TBL] [Abstract][Full Text] [Related]
10. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
Prather PL; FrancisDevaraj F; Dates CR; Greer AK; Bratton SM; Ford BM; Franks LN; Radominska-Pandya A
Biochem Biophys Res Commun; 2013 Nov; 441(2):339-43. PubMed ID: 24148245
[TBL] [Abstract][Full Text] [Related]
11. [Nuclear receptors--watchful mistrust of tamoxifen].
Dingermann T; Zündorf I
Pharm Unserer Zeit; 2004; 33(5):350-1. PubMed ID: 15497327
[No Abstract] [Full Text] [Related]
12. Identification of Selective ERRγ Inverse Agonists.
Kim J; Im CY; Yoo EK; Ma MJ; Kim SB; Hong E; Chin J; Hwang H; Lee S; Kim ND; Jeon JH; Lee IK; Jeon YH; Choi HS; Kim SH; Cho SJ
Molecules; 2016 Jan; 21(1):80. PubMed ID: 26771593
[TBL] [Abstract][Full Text] [Related]
13. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators.
McDonnell DP; Connor CE; Wijayaratne A; Chang CY; Norris JD
Recent Prog Horm Res; 2002; 57():295-316. PubMed ID: 12017549
[TBL] [Abstract][Full Text] [Related]
14. Effects of a combined treatment with tamoxifen and estrogen receptor β agonists on human breast cancer cell lines.
Lattrich C; Schüler S; Häring J; Skrzypczak M; Ortmann O; Treeck O
Arch Gynecol Obstet; 2014 Jan; 289(1):163-71. PubMed ID: 23907354
[TBL] [Abstract][Full Text] [Related]
15. Coactivators PGC-1beta and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator tamoxifen.
Kressler D; Hock MB; Kralli A
J Biol Chem; 2007 Sep; 282(37):26897-26907. PubMed ID: 17631495
[TBL] [Abstract][Full Text] [Related]
16. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
17. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
18. The science of selective estrogen receptor modulators: concept to clinical practice.
Jordan VC
Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
[No Abstract] [Full Text] [Related]
19. Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
Xiong R; Patel HK; Gutgesell LM; Zhao J; Delgado-Rivera L; Pham TND; Zhao H; Carlson K; Martin T; Katzenellenbogen JA; Moore TW; Tonetti DA; Thatcher GRJ
J Med Chem; 2016 Jan; 59(1):219-237. PubMed ID: 26681208
[TBL] [Abstract][Full Text] [Related]
20. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Park WC; Jordan VC
Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
